<DOC>
	<DOCNO>NCT01281384</DOCNO>
	<brief_summary>Uncovering underlie cause heart failure quite challenging doctor often rely image test echo ( heart ultrasound ) provide answer . Cardiac MRI emerge another promising test give precise information heart function amount scar muscle . Heart failure patient increasingly send cardiac MRI potential advantage test offer others echo fully explore . The purpose study determine cardiac MRI provide information cause heart failure traditional test echo . In addition , information provide test always lead overall improvement patient 's heart condition time . This randomized study subject refer clinically indicate heart failure workup determine best clinical management undergo standard heart failure test ( include echo ) OR standard test PLUS cardiac MRI .</brief_summary>
	<brief_title>Routine v Selective Cardiac Magnetic Resonance Non-Ischemic Heart Failure</brief_title>
	<detailed_description>Primary objective : compare effect routine cardiac magnetic resonance ( CMR ) versus standard care ( i.e . echocardiography selective use CMR ) etiological diagnosis patient non-ischemic heart failure ( HF ) . The proposed category HF consider study include : idiopathic dilate cardiomyopathy , infiltrative cardiomyopathy , inflammatory , hypertrophic cardiomyopathy , heart failure preserve ejection fraction ( HFPEF ) , ischemic cardiomyopathy , mixed etiology ( eg . pericardial , congenital , non-compaction , right ventricular failure ) . Primary hypothesis : Routine use CMR ( vs. selective use ) lead specific diagnostic characterization underlie etiology non-ischemic heart failure . This lead reduction diagnosis idiopathic dilate cardiomyopathy HFPEF . Secondary objective : Determine effect routine use CMR non-ischemic HF therapeutic decision , Composite Clinical Endpoint ( CCE ) , cardiac function , symptom , quality life ( QoL ) , cost . Ancillary measurement include safety image test adverse reaction gadolinium contrast agent . Secondary hypothesis : Routine use CMR significant impact treatment decision , ( 1 ) lead disease specific therapy and/or ( 2 ) cause significant change number class HF med , follow-up . The routine CMR group also improve clinical outcome ( CCE ) , symptoms QoL decrease cost standard care group follow-up . Design Methods : Randomized control trial comparing ) routine CMR vs. ii ) echocardiography selective CMR patient HF due NICM and/or HFPEF . Among patient enrol Level I IMAGE-HF , expect 504 know NICM ( strongly suspect base young age , absent risk factor present history ) and/or HFPEF . Tertiary care site ( Canada Finland ) dedicate HF program participate study . Consecutive patient enrol site dedicate CMR program ( define minimum 200 cases/year maximum 2 week wait time majority patient ) randomize routine CMR selective CMR . Non-ischemic HF patient sit without dedicate CMR program include registry patient undergoing routine HF care ( i.e . selective use CMR ) . Participants selective CMR arm may ONLY undergo CMR suspicion : 1 ) infiltrative myocardial disease , 2 ) arrhythmogenic right ventricular cardiomyopathy , 3 ) adult congenital heart disease 4 ) pericardial disease follow standard HF care include echocardiography . Other tertiary site may add year 2-3 depend recruitment need registry site may become randomization site experience wait-time criterion meet .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>The study population include patient either 1 . Newly diagnose HF within past 12 month OR 2 . Established HF patient deterioration/decompensation within past 12 month Patients new worsen HF AND 1 . Age &gt; 18 2 . Working clinical diagnosis ( know highly suspect ) nonischemic cardiomyopathy ( NICM ) OR Clinical diagnosis HFPEF ( Signs symptom heart failure LVEF â‰¥ 40 % ) 3 . Documented history Class IIIV NYHA HF symptom within past 12 month 1 . Prior CMR major change clinical condition 2 . Welldocumented specific etiology ( eg know amyloidosis hemochromatosis ) 3 . MD considers cause heart failure attributable obstructive CAD . 4 . Documented previous STEMI ( territory ) NSTEMI LAD territory 5 . Severe medical condition significantly affect patient 's outcome ( eg . active malignancy ) 6 . Ongoing need advance cardiac life support ( eg IABP ) 7 . Severe valvular heart disease require surgery within next 6 month 8 . Contraindications CMR ( e.g . certain metallic implant , severe claustrophobia ) 9 . Contraindications gadolinium contrast agent ( GFR &lt; 30ml/min/1,72m2 , pregnancy ) 10 . Inability give inform consent 11 . Evidence multivessel ischemia stress imaging</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cardiac magnetic resonance imaging</keyword>
	<keyword>echocardiography</keyword>
	<keyword>heart failure</keyword>
	<keyword>image</keyword>
	<keyword>cost effectiveness</keyword>
	<keyword>quality life</keyword>
	<keyword>definitive diagnosis</keyword>
	<keyword>prospective comparative effectiveness randomize clinical trial</keyword>
</DOC>